pHion Therapeutics is a UK based vaccine development company, developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and DNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo, irrespective of size into nanoparticles, which are highly efficient at cellular entry. The platform has the added advantage of ease of scalability and logistics, including stability at room temperature. pHion’s lead product is a therapeutic vaccine against HPV driven cancers (PTX_V1), with Phase I/IIA clinical trials planned to commence in 2023. pHion’s pipeline programs also include therapeutics against, ovarian (PTX_V5), prostate (PTX _V3), pancreatic cancers (PTX_C1), and a next generation COVID-19 mRNA vaccine that codes for multiple antigens. The company is headquartered in Belfast, Northern Ireland, with additional presence at Alderley Park, England.